About: Cricket paralysis virus internal ribosome entry site-derived RNA promotes conventional vaccine efficacy by enhancing a balanced Th1/Th2 response

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Cricket paralysis virus internal ribosome entry site-derived RNA promotes conventional vaccine efficacy by enhancing a balanced Th1/Th2 response Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Cricket paralysis virus internal ribosome entry site-derived RNA promotes conventional vaccine efficacy by enhancing a balanced Th1/Th2 response
Creator	Shin, Eui-Cheol Kim, Jae-Ouk Lee, Sang-Myeong Kim, Hye-Jung Nam, Jae-Hwan Kim, Hun Kim, Rhoon-Ho Park, Hyelim Park, Hyo-Jung Song, Manki Dae, Gwin Ho Cha, Min Jeong, Kang, Kyung Ko, Hae Kwak, Hye Ryu, Seung
source	Elsevier; Medline; PMC
abstract	Abstract An ideal adjuvant should increase vaccine efficacy through balanced Th1/Th2 responses and be safe to use. Recombinant protein-based vaccines are usually formulated with aluminum (alum)-based adjuvants to ensure an adequate immune response. However, use of alum triggers a Th2-biased immune induction, and hence is not optimal. Although the adjuvanticity of RNA has been reported, a systematic and overall investigation on its efficacy is lacking. We found that single strand RNA (termed RNA adjuvant) derived from cricket paralysis virus intergenic region internal ribosome entry site induced the expression of various adjuvant-function-related genes, such as type 1 and 2 interferon (IFN) and toll-like receptor (TLR), T cell activation, and leukocyte chemotaxis in human peripheral blood mononuclear cells; furthermore, its innate and IFN transcriptome profile patterns were similar to those of a live-attenuated yellow fever vaccine. This suggests that protein-based vaccines formulated using RNA adjuvant function as live-attenuated vaccines. Application of the RNA adjuvant in mouse enhanced the efficacy of Middle East respiratory syndrome spike protein, a protein-subunit vaccine and human papillomavirus L1 protein, a virus-like particle vaccine, by activating innate immune response through TLR7 and enhancing pAPC chemotaxis, leading to a balanced Th1/Th2 responses. Moreover, the combination of alum and the RNA adjuvant synergistically induced humoral and cellular immune responses and endowed long-term immunity. Therefore, RNA adjuvants have broad applicability and can be used with all conventional vaccines to improve vaccine efficacy qualitatively and quantitively.
has issue date	2019-08-23(xsd:dateTime)
bibo:doi	10.1016/j.vaccine.2019.07.070
bibo:pmid	31371226
has license	els-covid
sha1sum (hex)	53ad783bd651dab3f1ff08e681a286db611075aa
schema:url	https://doi.org/10.1016/j.vaccine.2019.07.070
resource representing a document's title	Cricket paralysis virus internal ribosome entry site-derived RNA promotes conventional vaccine efficacy by enhancing a balanced Th1/Th2 response
has PubMed Central identifier	PMC7115557
has PubMed identifier	31371226
schema:publication	Vaccine
resource representing a document's body	covid:53ad783bd651dab3f1ff08e681a286db611075aa#body_text
is schema:about of	named entity 'profile' named entity 'interferon' named entity 'innate' named entity 'TLR' named entity 'type 1' named entity 'induced' named entity 'Th1' named entity 'ensure' named entity 'CONVENTIONAL' named entity 'S T' named entity 'CELLULAR' named entity 'YELLOW FEVER VACCINE' named entity 'RNA' named entity 'OPTIMAL' named entity 'USE' named entity 'VARIOUS' named entity 'INTERFERON ' named entity 'INTERGENIC REGION' named entity 'IDEAL' named entity 'LIVE' named entity 'ENSURE' named entity 'SPIKE PROTEIN' named entity 'INVESTIGATION' named entity 'IMMUNITY' named entity 'ENHANCING' named entity 'PAPC' named entity 'USING' named entity 'VACCINES' covid:arg/53ad783bd651dab3f1ff08e681a286db611075aa named entity 'RESPONSES' named entity 'BROAD' named entity 'FOUND' named entity 'TH2' named entity 'HPV' named entity 'HAVE' named entity 'INCREASE' named entity 'ADEQUATE' named entity 'ALUMINUM' named entity 'CHEMOTAXIS' named entity 'MIDDLE EAST RESPIRATORY SYNDROME ' named entity 'BIASED' named entity 'ATTENUATED' named entity 'SINGLE STRAND RNA' named entity 'OVERALL' named entity 'TYPE 1' named entity 'VACCINE' named entity 'RELATED' named entity 'CRPV' named entity 'ACTIVATING' named entity 'EXPRESSION' named entity 'LONG-TERM' named entity 'PATTERNS' named entity 'LACKING' named entity 'SUBUNIT VACCINE' named entity 'PERIPHERAL BLOOD MONONUCLEAR CELLS' named entity 'HUMAN' named entity 'COMBINATION' named entity 'INNATE IMMUNE RESPONSE' named entity 'LEADING' named entity 'TLR7' named entity 'IMMUNE INDUCTION' named entity 'BALANCED' named entity 'CRICKET PARALYSIS VIRUS' named entity 'TH1' named entity 'INTERNAL RIBOSOME ENTRY SITE'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software